Nature’s Fynd to Debut Fy Bites and Fy Culinary Base at the 2025 National Restaurant Association ShowRevolutionizing Foodservice with Nutrient-Dense, Big 9 Allergen-Free, and Versatile Fungi-Powered Offerings
Complete Solaria, Inc. Announces Rebrand as SunPowerOREM, Utah, April 21, 2025 (GLOBE NEWSWIRE) -- Complete Solaria, Inc. d/b/a SunPower (“SunPower” or the “Company”) (Nasdaq: CSLR), a leading solar technology, services, and installation company, today announced it is rebranding as SunPower. The company’s ticker symbol will change from “CSLR” and “CSLRW” to “SPWR” and “SPWRW”, respectively, effective April 22, 2025.
Snail Games Subsidiary Interactive Films LLC Signs MOU with Mega Matrix Inc. (NYSE American: MPU) for Joint Short-Drama DevelopmentCULVER CITY, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- Snail, Inc. (Nasdaq: SNAL) (“Snail Games” or the “Company”), a leading global independent developer and publisher of interactive digital entertainment, announced that its wholly owned subsidiary, Interactive Films LLC (“Interactive Films”), has signed a Memorandum of Understanding (MOU) with Mega Matrix Inc. (NYSE American: MPU). Under this MOU, both parties will leverage their respective strengths to establish a comprehensive collaboration framework for the joint development, production, and global distribution of short dramas, further enhancing their presence in the entertainment industry.
Joshua Grass, John Kelly, and Lauren Daniel Join 5AM VenturesEnhancing the depth of 5AM’s operational & scientific expertise
BigCommerce and Feedonomics Announce Winners of Americas Region Customer and Partner Awards to Honor Exceptional Contributions and Results in EcommerceEcommerce leaders honor the most innovative customers and agency and technology partners for their work pushing ecommerce boundaries to new levels of success
Chemomab Therapeutics to Present Nebokitug Clinical Data at Upcoming Scientific ConferencesTEL AVIV, Israel, April 21, 2025 (GLOBE NEWSWIRE) -- Chemomab Therapeutics, Ltd., (Nasdaq: CMMB), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that clinical data on nebokitug (CM-101) for the treatment of patients with primary sclerosing cholangitis (PSC) will be presented at major upcoming scientific conferences including DDW25, Digestive Disease Week 2025®; EASL 2025, the Annual Congress of the European Association for the Study of the Liver; and BSG LIVE'25, the British Society of Gastroenterology’s annual meeting. Chemomab will report information on the content of the presentations after the meeting embargoes lift.
Nexalin Technology Expresses Strong Support for Health Tech Investment Act to Advance Medicare Reimbursement for AI-Enabled DevicesProposed bipartisan legislation would expand Medicare reimbursement pathways for AI-enabled medical devices — a framework that supports Nexalin’s Gen-3 HALO Clarity™ neurostimulation device integrated with artificial intelligence
North American Construction Group Ltd. First Quarter Results Conference Call and Webcast NotificationACHESON, Alberta, April 21, 2025 (GLOBE NEWSWIRE) -- North American Construction Group Ltd. (“NACG” or “the Company”) (TSX:NOA.TO/NYSE:NOA) announced today that it will release its financial results for the first quarter ended March 31, 2025 on Wednesday, May 14, 2025 after markets close. Following the release of its financial results, NACG will hold a conference call and webcast on Thursday, May 15, 2025, at 7:00 a.m. Mountain Time (9:00 a.m. Eastern Time).
BlueGrace Logistics Announces 2025 LTL Summit at Tampa HeadquartersEvent brings top Less-Than-Truckload (LTL) carriers, technology partners, and thought leaders from across the logistics industry together
Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAPBRISBANE, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated therapeutics to fight cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to TPST-1495, the company’s novel dual receptor inhibitor of prostaglandin (PGE2) signaling, for the treatment of patients with Familial Adenomatous Polyposis (FAP).
Compass Lexecon Adds Valuation Expert Faten Sabry as Senior Managing DirectorWASHINGTON, April 21, 2025 (GLOBE NEWSWIRE) -- Compass Lexecon, a subsidiary of FTI Consulting, Inc. (
NYSE: FCN), today announced that Faten Sabry has joined the firm as a Senior Managing Director.
Nano Dimension Provides Update on Desktop MetalWaltham, Massachusetts, April 21, 2025 (GLOBE NEWSWIRE) -- Nano Dimension Ltd. (Nasdaq: NNDM) (“Nano Dimension” or the “Company”), a leader in Digital Manufacturing solutions, today provided an update on Desktop Metal.
Invivyd Announces $30M Non-dilutive Loan Facility with Silicon Valley BankWALTHAM, Mass., April 21, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that it has signed a $30 million term loan facility with Silicon Valley Bank (SVB), a division of First Citizens Bank. The deal allows for drawdown of capital in the future if certain conditions and milestones are met.
Northland Power Appoints New Chief Financial OfficerTORONTO, April 21, 2025 (GLOBE NEWSWIRE) -- Northland Power Inc. (TSX: NPI) (“Northland” or the “Company”) announced today the appointment of Jeff Hart as the Company’s new Chief Financial Officer (CFO), effective May 1, 2025.
Ascentage Pharma Announces Inclusion of Lisaftoclax and Olverembatinib in Chinese Society of Clinical Oncology (CSCO) 2025 GuidelinesROCKVILLE, Md. and SUZHOU, China, April 21, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for hematological malignancies, today announced that two of its proprietary novel drugs have been included in the 2025 Chinese Society of Clinical Oncology (CSCO) Guidelines. Lisaftoclax (APG-2575), the company’s investigational novel oral Bcl-2 selective inhibitor, received its first recommendation in the CSCO Guidelines for the Diagnosis and Treatment of Lymphoid Malignancies. Olverembatinib, the company’s novel next-generation tyrosine kinase inhibitor (TKI), received an upgraded recommendation in the CSCO Guidelines for the Diagnosis and Treatment of Leukemias in Children and Adolescent, and retained its recommendations in the CSCO Guidelines for the Diagnosis and Treatment of Hematological Malignancies.
USA Rare Earth Announces Date for First Quarter 2025 Results and Conference CallSTILLWATER, Okla., April 21, 2025 (GLOBE NEWSWIRE) -- USA Rare Earth, Inc. (Nasdaq: USAR) (USAR or the Company), today announced that it will release financial results for the quarterly period ended March 31, 2025, after U.S. markets close on Wednesday, May 14, 2025. Additionally, the Company will host a conference call that afternoon to discuss the results and related matters.
Amicus Therapeutics to Announce First Quarter 2025 Financial Results on May 1, 2025PRINCETON, N.J., April 21, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, May 1, 2025, at 8:30 a.m. ET to discuss financial results for the first quarter ended March 31, 2025.
PX Energy, an Expanding Vertically Integrated Refinery and Mining Operation Located in Southern Brazil, Intends to Go Public Through a Business Combination with Papaya Growth Opportunity Corp. I, Including a Committed $10 Million InvestmentTORONTO, April 21, 2025 (GLOBE NEWSWIRE) -- PX Energy (“PX” or the “Company”), a vertically-integrated refined products manufacturer serving the Brazilian market for refined oil and agricultural grade products (through its parent company, Forbes & Manhattan Resources Inc.), and Papaya Growth Opportunity Corp. I (“PPYA”) announced today that they have entered into a definitive business combination agreement (the “BCA” and the transactions contemplated under the BCA, the “Business Combination” or the “Transaction”). Upon the completion of the Business Combination, the combined company will retain its name “PX Energy” and its headquarters in Brazil, and its ordinary shares to be listed on Nasdaq. PX Energy website is located at: https://pxenergy.com.br
OTC Markets Group Announces Quarterly Index Performance and RebalancingNEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated financial markets for 12,000 U.S. and global securities, today announced the first quarter 2025 performance and quarterly rebalancing of the OTCQX® indexes, including the OTCQX Canada Index and the OTCQX Dividend Index.
OTC Markets Group Welcomes Enzo Biochem, Inc. to OTCQXNEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Enzo Biochem, Inc. (OTCQX: ENZB), life sciences company, has qualified to trade on the OTCQX® Best Market. Enzo Biochem, Inc. previously traded on the New York Stock Exchange.
CECO Environmental to Release First Quarter Earnings and Host Conference Call on April 29ADDISON, Texas, April 21, 2025 (GLOBE NEWSWIRE) -- CECO Environmental Corp. (Nasdaq: CECO), a leading environmentally focused, diversified industrial company whose solutions protect people, the environment and industrial equipment, today announced that it will report its first quarter of 2025 financial results on April 29, 2025, premarket. The Company will also host its earnings call starting at 8:30 a.m. Eastern Time (7:30 a.m. CT). The Company’s financial results and presentation will be posted on its website at www.cecoenviro.com.
Apellis Announces Craig Wheeler to Join the Board of DirectorsWALTHAM, Mass., April 21, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that Craig Wheeler, founder and chief executive officer of Headwaters Biotech Advisors, will join the Apellis Board of Directors, effective immediately. Mr. Wheeler is a highly accomplished executive with more than 30 years of leadership experience across the biopharmaceutical industry.
AccuStem Sciences, Inc. Announces Chairman Purchase of SharesLONDON and PHOENIX, Ariz., April 21, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, announced that its Chairman of the Board, Mr. Gabriele Cerrone, has notified the Company that he has recently purchased an additional 5,000 ACUT shares in the open market. This brings his total holding to 4,915,759 shares.
Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjögren’s Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced next phase of growth including changes to its leadership team and the expanded development of IMVT-1402 into two new indications, SjD and CLE.
Blue Moon Metals Appoints Boi Linh Doig as Vice-President, MiningTORONTO, April 21, 2025 (GLOBE NEWSWIRE) -- Blue Moon Metals Inc. (“Blue Moon” or the “Company”) (TSXV: MOON; OTCQX: BMOOF), is pleased to announce the appointment of Boi Linh Doig as Vice-President, Mining, as it continues to build out its management team to support the Company's continued growth in the development of its three polymetallic brownfield projects.
Alumis and ACELYRIN Announce Amended Merger AgreementACELYRIN stockholders to receive increased ownership in the combined company through revised exchange ratio; Alumis and ACELYRIN stockholders to now own approximately 52% and 48%, respectively, of the combined company on a fully diluted basis
Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price RequirementMANNHEIM, Germany, April 21, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it has received a written notice (the “Notice”), dated April 15, 2025, from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, for the last thirty (30) consecutive business days, the bid price for the Company’s common shares had closed below the minimum $1.00 per share requirement for continued listing on the Nasdaq under Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Rule”).
Zymeworks Appoints Dr. Sabeen Mekan as Senior Vice President, Clinical DevelopmentVANCOUVER, British Columbia, April 21, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced that Sabeen Mekan, M.D., has been appointed as Senior Vice President, Clinical Development. Reporting directly to the Chief Executive Officer, Dr. Mekan will have a key role in formulating the clinical development strategy for Zymeworks' clinical-stage oncology portfolio, including global regulatory affairs. Dr. Jeff Smith, who joined Zymeworks in 2023, will continue as Executive Vice President & Chief Medical Officer, with primary responsibility for Zymeworks’ emerging R&D portfolio in autoimmune and inflammatory disease and Global Clincal Development Operations. Ms. Barbara Schaeffler, who joined Zymeworks in 2024, has been promoted to Senior Vice President, Clinical Development Operations, reporting to Dr. Smith.
Jeffs’ Brands: Fort Submits Android Version of AI-Based Pest Control App to Google PlayTel Aviv, Israel, April 21, 2025 (GLOBE NEWSWIRE) -- Jeffs' Brands Ltd (“Jeffs’ Brands” or the “Company”) (Nasdaq: JFBR, JFBRW), a data-driven e-commerce company operating on the Amazon Marketplace, announced today that its wholly-owned subsidiary, Fort Products Limited (“Fort”), has submitted the Android version of its artificial intelligence (AI)-powered pest control mobile application for review on Google Play. This follows the successful completion of the development and internal testing of the mobile app, marking a major milestone as Fort transitions from internal validation towards commercial rollout.
Niu Technologies to Report First Quarter 2025 Financial Results on May 19, 2025BEIJING, April 21, 2025 (GLOBE NEWSWIRE) -- Niu Technologies (“NIU” or “the Company”) (
NASDAQ: NIU), the world’s leading provider of smart urban mobility solutions, today announced that it will report its financial results for the first quarter 2025 before the U.S. market opens on Monday, May 19, 2025.
Tumella Unveils the Strongest Folding Umbrella on the Market, Setting a New Standard for DurabilityDutch Company Redefines Expectations for Compact Travel Umbrellas with Wind Resistance up to 70 MPH
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rocket Lab USAFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Rocket Lab To Contact Him Directly To Discuss Their Options
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of e.l.f. BeautyFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In e.l.f. Beauty To Contact Him Directly To Discuss Their Options
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of IbottaFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Ibotta To Contact Him Directly To Discuss Their Options
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ultra CleanFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Ultra Clean To Contact Him Directly To Discuss Their Options
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of enCoreFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In enCore To Contact Him Directly To Discuss Their Options
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of The BancorpFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In The Bancorp To Contact Him Directly To Discuss Their Options
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Perpetua Resources Corp.Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Perpetua To Contact Him Directly To Discuss Their Options
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ready CapitalFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Ready Capital To Contact Him Directly To Discuss Their Options
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of SkyworksFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Skyworks To Contact Him Directly To Discuss Their Options
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Constellation BrandsFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Constellation Brands To Contact Him Directly To Discuss Their Options
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of AppLovinFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In AppLovin To Contact Him Directly To Discuss Their Options
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of EverusFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Everus To Contact Him Directly To Discuss Their Options
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of ActiniumFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Actinium To Contact Him Directly To Discuss Their Options
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Solaris EnergyFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Solaris To Contact Him Directly To Discuss Their Options
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sana BiotechnologyFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Sana To Contact Him Directly To Discuss Their Options
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of SoundHound AIFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In SoundHound AI To Contact Him Directly To Discuss Their Options
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Edison InternationalFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Edison To Contact Him Directly To Discuss Their Options
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of TFI InternationalFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In TFI To Contact Him Directly To Discuss Their Options
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of BigBear.aiFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In BigBear.ai To Contact Him Directly To Discuss Their Options
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Manhattan AssociatesFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Manhattan Associates To Contact Him Directly To Discuss Their Options
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharmaFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Zenas To Contact Him Directly To Discuss Their Options
